

May 27, 2025

Brain Tumour Foundation of Canada has recently learned that Health Canada has granted a shelf-life extension for additional lots of lomustine (CeeNU).

The following lots of CeeNU are now set to expire as follows:

- CeeNU 10 mg capsules (lot 2H02104 and 2H02101) have a labelled expiry date of May 2025. The shelf-life for this lot has been extended to **November 2025**.
- CeeNU 40 mg capsules (lot 2J06575 and 2J06574) have a labelled expiry date of June 2025. The shelf-life for this lot has been extended to **December 2025**.

Product / Strength	DIN	Lot	Expiry date printed Label	Approved Extended Expiry Date
CeeNU 10mg	00360430	2H02104 2H02101	2025 / 05	2025 / 11
CeeNU 40mg	00360422	2J06575 2J06574	2025 / 06	2025 / 12

[Click here to view the details of the supply notice.](#)

Ensuring continued access to lomustine is a top priority. Brain Tumour Foundation of Canada is communicating with governing bodies, such as Health Canada, to coordinate the sharing of information about the pending discontinuation. Health Canada continues to work with manufacturers and stakeholders to identify strategies to ensure continued access to lomustine for Canadian patients following the discontinuation of CeeNU (lomustine).

In the meantime, Health Canada has authorized the importation of lomustine capsules (10 mg and 40 mg) as an interim measure to allow for uninterrupted access to lomustine. Visit the [List of Drugs for Exceptional Importation and Sale](#) for more details.

Speak with your healthcare team or pharmacist if you have questions or concerns about how these changes may impact access to your prescribed medications.

If you have questions or concerns about Brain Tumour Foundation of Canada's advocacy efforts, please contact:

Sarah Rogers, healthcare partnerships and advocacy specialist
srogers@braintumour.ca

